Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierGilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q2 2026 · $8.54BThe company’s own SEC segment disclosure.
- HIV Product Sales$4.66B55%
- HIV Products Descovy$921.0M11%
- Oncology Product$468.0M5%
- Liver Disease$433.0M5%
- Trodelvy$307.0M4%
- HIV Products Genvoya$236.0M3%
- Other (16)$1.52B18%
Gilead Sciences (GILD) reported revenue of $7.80B in Q2 2026 (quarter ended June 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 80% and net loss of $10.5B. For the full year FY2025, revenue was $29.4B (+2.4% year on year) and net income $8.51B. Its largest product in 2026-Q2 was HIV Product Sales at $4.66B, 55% of the disclosed total, just ahead of HIV Products Descovy at 11%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - General
Ranks #6 of 16 by Smart Score